Tulisokibart Posts Efficacy in Phase 2b for Moderate-to-Severe HS
Tulisokibart demonstrated efficacy in a Phase 2b study of patients with moderate to severe hidradenitis suppurativa, HCPLive reports, marking the candidate as one to watch.
Topic
Hiscr
Topic